

Sevim Türktekin,^a Mehmet Akkurt,^{a*} Ersin Orhan,^b F. Zehra Küçükbay,^c Hasan Küçükbay^d and Orhan Büyükgüngör^e

^aDepartment of Physics, Faculty of Arts and Sciences, Erciyes University, 38039 Kayseri, Turkey, ^bDepartment of Chemistry, Faculty of Arts and Sciences, Karaelmas University, 67100 Zonguldak, Turkey, ^cDepartment of Analytical Chemistry, Basic Pharmaceutical Sciences, Faculty of Pharmacy, İnönü University, 44280 Malatya, Turkey, ^dDepartment of Chemistry, Faculty of Arts and Sciences, İnönü University, 44280 Malatya, Turkey, and ^eDepartment of Physics, Faculty of Arts and Sciences, Ondokuz Mayıs University, 55139 Samsun, Turkey

Correspondence e-mail: akkurt@erciyes.edu.tr

Key indicators

Single-crystal X-ray study
T = 150 K
Mean $\sigma(\text{C}-\text{C}) = 0.004 \text{ \AA}$
R factor = 0.030
wR factor = 0.073
Data-to-parameter ratio = 20.6

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


Dichlorobis[1-(2-ethoxyethyl)-1H-benzimidazole- κN^3]cobalt(II)

The title compound, $[\text{CoCl}_2(\text{C}_{11}\text{H}_{14}\text{N}_2\text{O})_2]$, was synthesized from 1-(2-ethoxyethyl)benzimidazole and cobalt dichloride in ethanol. The Co^{II} atom is coordinated in a distorted tetrahedral environment by two Cl atoms and two N atoms. The crystal structure is stabilized by intermolecular $\text{C}-\text{H}\cdots\text{Cl}$ and $\text{C}-\text{H}\cdots\text{O}$ interactions.

Received 29 July 2004
Accepted 2 August 2004
Online 7 August 2004

Comment

Benzimidazole and its derivatives have been found to have a broad range of pharmacological activity (Küçükbay *et al.*, 2001, 2004; Küçükbay, Durmaz, Orhan & Günel, 2003; Küçükbay, Durmaz, Okuyucu & Günel, 2003; Tavman, 2003). Transition metal complexes of benzimidazoles are increasingly used to model important bioinorganic systems (Khalil *et al.*, 2001). Furthermore, benzimidazole complexes have been evaluated as antifungal (Küçükbay & Durmaz, 1997), antibacterial (Çetinkaya *et al.*, 1996) and antitumour agents (Lukevics *et al.*, 2001). We have also synthesized a number of rhodium and ruthenium complexes of benzimidazole derivatives and determined their antimicrobial properties (Küçükbay & Durmaz, 1997; Durmaz *et al.*, 1997; Çetinkaya *et al.*, 1996), while results for related compounds containing the benzimidazole moiety have been reported in our earlier papers (Öztürk *et al.*, 2004; Akkurt, Öztürk, Küçükbay *et al.*, 2004a,b; Akkurt, Öztürk, Şireci *et al.*, 2004; Türktekin *et al.*, 2004). The aim of the present study was to elucidate the crystal structure of the title compound, (I).



The Co atom in (I) is coordinated tetrahedrally by two Cl atoms and two N atoms (Fig. 1 and Table 1). The Cl_2N_2 donor set defines a distorted tetrahedron, with angles ranging from $104.61(5)^\circ$ to $119.84(2)^\circ$.

The average Co–N bond length of $2.008(2) \text{ \AA}$ may be compared with the reported average values of $2.1653(16) \text{ \AA}$ for *trans*-tetraaquabis(*p*-nitrobenzoxasulfamato)cobalt(II) (Kazak *et al.*, 2004), $2.0944(14) \text{ \AA}$ in diaquabis(1*H*-imidazole- κN^3)bis(4-nitrobenzoato- κO)cobalt(II) (Xu & Xu, 2004) and

2.159 (2) Å in diaquadiformatodipyridinecobalt(II) (Zhu *et al.*, 2004). The Co–N bond lengths are almost equal to the value of 2.008 (3) Å observed in *trans*-diaquabis(pyridine-4-carboxylato)cobalt(II)dihydrate (Yan, 2004).

The Co–Cl bond lengths of 2.2423 (6) and 2.5616 (6) Å in (I) are nearly equal to the corresponding lengths reported for other compounds, *viz.* 2.2525 (8) Å in quinolinium trichloro(quinoline- κ N)cobaltate(II) (Pan & Xu, 2004) and 2.236 (1) Å in dichlorobis(1-propylimidazolidine-2-thione- κ S)cobalt(II) (Castro *et al.*, 2002), but shorter than the value of 2.391 (1) Å observed in aquachlorobis(1,10-phenanthroline)-cobalt(II)chloride dimethyl formamide solvate (Liu *et al.*, 2004).

The dihedral angle between the least-squares planes through the two benzimidazole ring systems is 81.78 (8)°. In the crystal structure of (I), individual molecules are loosely associated into pairs *via* C–H...Cl and C–H...O hydrogen-bonding interactions (Fig. 2 and Table 2).

Experimental

1-(2-Ethoxyethyl)benzimidazole was synthesized from benzimidazole and 2-chloroethyl ethyl ether according to the literature procedure of Küçükbay *et al.* (2001). A mixture of 1-(2-ethoxyethyl)benzimidazole (0.4 g, 2.10 mmol) and cobalt dichloride (0.27 g, 2.10 mmol) in ethanol (25 ml) was heated under reflux for 4 h. All volatiles were removed *in vacuo* (0.02 mm Hg; 1 mm Hg = 133.322 Pa). The crude product, (I), was crystallized from an ethanol–propan-2-ol (3:1) mixture upon cooling to 243 K (yield 0.93 g, 86%; m.p. 434–435 K). ¹H NMR (300 MHz, CDCl₃, p.p.m.): 1.1 (*t*, CH₃CH₂–O, 6H), 3.3 (*q*, CH₃CH₂–O, 4H), 3.7 (*s*, NCH₂CH₂–O, 4H), 3.9 (*t*, NCH₂CH₂–O, 4H), 7.8–8.2 (*m*, Ar-H, 8H), 8.3 (*s*, 2-CH, 2H). Analysis, calculated for C₂₂H₂₈N₄O₂CoCl₂: C 51.66, H 5.48, N 10.96%; found: C 51.17, H 5.43, N 10.91%.

Crystal data

[CoCl ₂ (C ₁₁ H ₁₄ N ₂ O) ₂]	Mo K α radiation
$M_r = 510.31$	Cell parameters from 5762 reflections
Orthorhombic, <i>Pca</i> 2 ₁	$\theta = 1.6$ – 28.4°
$a = 17.5842$ (17) Å	$\mu = 0.96$ mm ⁻¹
$b = 7.6235$ (8) Å	$T = 150$ K
$c = 17.8892$ (13) Å	Prism, violet
$V = 2398.1$ (4) Å ³	$0.64 \times 0.50 \times 0.41$ mm
$Z = 4$	
$D_x = 1.413$ Mg m ⁻³	

Data collection

Stoe IPDS II diffractometer	5762 independent reflections
ω scans	5101 reflections with $I > 2\sigma(I)$
Absorption correction: by integration (<i>X-RED32</i> ;	$R_{int} = 0.031$
Stoe & Cie, 2002)	$\theta_{max} = 28.3^\circ$
$T_{min} = 0.577$, $T_{max} = 0.693$	$h = -23 \rightarrow 23$
15 539 measured reflections	$k = -10 \rightarrow 10$
	$l = -23 \rightarrow 22$

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0489P)^2]$
$R[F^2 > 2\sigma(F^2)] = 0.030$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.073$	$(\Delta/\sigma)_{max} = 0.001$
$S = 0.98$	$\Delta\rho_{max} = 0.50$ e Å ⁻³
5762 reflections	$\Delta\rho_{min} = -0.32$ e Å ⁻³
280 parameters	Absolute structure: Flack (1983),
H-atom parameters constrained	with 2688 Friedel pairs
	Flack parameter = 0.000 (1)




Figure 1

A view of the molecule of (I), with the atom-numbering scheme. Displacement ellipsoids are drawn at the 20% probability level and H atoms are shown as small spheres of arbitrary radii.

Table 1

Selected geometric parameters (Å, °).

Co1–Cl1	2.2423 (6)	N1–C2	1.392 (3)
Co1–Cl2	2.2516 (6)	N2–C1	1.343 (3)
Co1–N1	2.014 (2)	N2–C7	1.383 (3)
Co1–N3	2.0021 (16)	N2–C8	1.456 (3)
O1–C9	1.417 (3)	N3–C12	1.307 (3)
O1–C10	1.433 (3)	N3–C13	1.394 (2)
O2–C20	1.395 (4)	N4–C12	1.345 (3)
O2–C21	1.447 (4)	N4–C18	1.387 (3)
N1–C1	1.315 (3)	N4–C19	1.455 (3)
Cl1–Co1–Cl2	119.84 (2)	Cl2–N4–C19	125.62 (19)
Cl1–Co1–N1	108.89 (5)	Cl8–N4–C19	127.26 (19)
Cl1–Co1–N3	104.61 (5)	N1–C1–N2	113.1 (2)
Cl2–Co1–N1	108.86 (5)	N1–C2–C3	131.1 (2)
Cl2–Co1–N3	107.27 (5)	N1–C2–C7	108.79 (19)
N1–Co1–N3	106.57 (7)	N2–C7–C2	105.5 (2)
C9–O1–C10	111.09 (18)	N2–C7–C6	131.7 (2)
C20–O2–C21	116.5 (3)	N2–C8–C9	111.8 (2)
Co1–N1–C1	125.78 (15)	O1–C9–C8	108.63 (19)
Co1–N1–C2	128.56 (14)	O1–C10–C11	108.8 (2)
C1–N1–C2	105.45 (19)	N3–C12–N4	113.03 (19)
C1–N2–C7	107.2 (2)	N3–C13–C14	130.84 (19)
C1–N2–C8	126.5 (2)	N3–C13–C18	108.27 (19)
C7–N2–C8	126.1 (2)	N4–C18–C13	105.75 (18)
Co1–N3–C12	127.09 (14)	N4–C18–C17	132.3 (2)
Co1–N3–C13	126.85 (14)	N4–C19–C20	112.2 (2)
Cl2–N3–C13	106.04 (17)	O2–C20–C19	108.9 (2)
Cl2–N4–C18	106.91 (17)	O2–C21–C22	116.3 (4)

Table 2

Hydrogen-bonding geometry (Å, °).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
C16–H16...Cl2 ⁱ	0.93	2.80	3.591 (3)	144
C17–H17...Cl1 ⁱⁱ	0.93	2.80	3.717 (2)	168
C20–H20A...O1 ⁱⁱⁱ	0.97	2.51	3.356 (3)	145

Symmetry codes: (i) $x - \frac{1}{2}, -y, z$; (ii) $x - \frac{1}{2}, 1 - y, z$; (iii) $\frac{1}{2} - x, 1 + y, \frac{1}{2} + z$.

H atoms were positioned geometrically, with C–H = 0.93–0.97 Å, and refined in a riding model, with $U_{iso}(H) = 1.5U_{eq}(C)$ for methyl H atoms and $1.2U_{eq}(C)$ for all other H atoms.




Figure 2
A view of the packing and hydrogen bonds (dashed lines) of (I).

Data collection: *X-AREA* (Stoe & Cie, 2002); cell refinement: *X-AREA*; data reduction: *X-RED32* (Stoe & Cie, 2002); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPIII* (Farrugia, 1997); software used to prepare material for publication: *WinGX* (Farrugia, 1999).

The authors acknowledge the Faculty of Arts and Sciences, Ondokuz Mayıs University, Turkey, for the use of the Stoe IPDS II diffractometer (purchased under grant No. F.279 of the University Research Fund). EO, FZK and HK also thank İnönü University Research Fund (grant No. 2002/06) for purchased the 300 MHz NMR spectrometer.

References

- Akkurt, M., Öztürk, S., Küçükbay, H., Orhan, E. & Büyükgüngör, O. (2004a). *Acta Cryst. E60*, o219–o221.
- Akkurt, M., Öztürk, S., Küçükbay, H., Orhan, E. & Büyükgüngör, O. (2004b). *Acta Cryst. E60*, o1263–o1265.
- Akkurt, M., Öztürk, S., Şireci, N., Küçükbay, H. & Büyükgüngör, O. (2004). *Acta Cryst. E60*, o1185–o1187.
- Castro, J., Lourido, P. P., Sousa-Pedraes, A., Labisbal, E., Piso, J. & Garcia-Vázquez, J. A. (2002). *Acta Cryst. C58*, m319–m322.
- Çetinkaya, B., Çetinkaya, E., Küçükbay, H. & Durmaz, R. (1996). *Arzneim. Forsch. (Drug Res.)*, **46**, 821–823.
- Durmaz, R., Küçükbay, H., Çetinkaya, E. & Çetinkaya, B. (1997). *Turk. J. Med. Sci.* **27**, 59–61.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Farrugia, L. J. (1999). *J. Appl. Cryst.* **32**, 837–838.
- Flack, H. D. (1983). *Acta Cryst. A39*, 876–881.
- Kazak, C., Yazıcılar, T. K. & Yılmaz, V. T. (2004). *Acta Cryst. E60*, m452–m454.
- Khalil, M. M. H., Saadia, A. A. & Ramadan, R. M. (2001). *Spectrochim. Acta A*, **57**, 1017–1024.
- Küçükbay, H. & Durmaz, R. (1997). *Arzneim. Forsch. (Drug Res.)*, **47**, 667–670.
- Küçükbay, H., Durmaz, R., Güven, M. & Günel, S. (2001). *Arzneim. Forsch. (Drug Res.)*, **51**, 420–424.
- Küçükbay, H., Durmaz, R., Okuyucu, N. & Günel, S. (2003). *Folia Microbiol.* **48**, 679–681.
- Küçükbay, H., Durmaz, R., Okuyucu, N., Günel, S. & Kazaz, C. (2004). *Arzneim. Forsch. (Drug Res.)*, **54**, 64–68.
- Küçükbay, H., Durmaz, R., Orhan, E. & Günel, S. (2003). *Farmaco*, **58**, 431–437.
- Liu, J.-W., Gao, S., Huo, L.-H. & Ng, S. W. (2004). *Acta Cryst. E60*, m501–m503.
- Lukevics, E., Arsenyan, P., Shestakova, I., Domracheva, I., Nesterova, A. & Pudova, O. (2001). *Eur. J. Med. Chem.* **36**, 507–515.
- Öztürk, S., Akkurt, M., Küçükbay, H., Orhan, E. & Büyükgüngör, O. (2004). *Acta Cryst. E60*, o936–o938.
- Pan, T.-T. & Xu, D.-J. (2004). *Acta Cryst. E60*, m56–m58.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Stoe & Cie (2002). *X-AREA* (Version 1.18) and *X-RED32* (Version 1.04). Stoe & Cie, Darmstadt, Germany.
- Tavman, A. (2003). *Main Group Met. Chem.* **26**, 229–235.
- Türktekin, S., Akkurt, M., Şireci, N., Küçükbay, H. & Büyükgüngör, O. (2004). *Acta Cryst. E60*, o817–o819.
- Xu, T.-G. & Xu, D.-J. (2004). *Acta Cryst. E60*, m131–m133.
- Yan, Z.-Q. (2004). *Acta Cryst. E60*, m116–m117.
- Zhu, Z.-B., Gao, S., Liu, J.-W., Huo, L.-H. & Zhao, H. (2004). *Acta Cryst. E60*, m808–m810.